Cargando…

Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study

Although Bacillus Calmette Guérin (BCG) remains a mainstay of adjuvant treatment in high-risk, non-muscle-invasive bladder cancer, BCG failure occurs in up to 40% of patients, with radical cystectomy (RC) as the inevitable therapeutic consequence. Current data suggest that PD-L1 immunosuppressive si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pichler, Renate, Lindner, Andrea Katharina, Schäfer, Georg, Tulchiner, Gennadi, Staudacher, Nina, Mayr, Martin, Comperat, Eva, Orme, Jacob J., Schachtner, Gert, Thurnher, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917772/ https://www.ncbi.nlm.nih.gov/pubmed/33672843 http://dx.doi.org/10.3390/jcm10040764

Ejemplares similares

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report
por: Lindner, Andrea Katharina, et al.
Publicado: (2018)

Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2022)

HUS1 as a Potential Therapeutic Target in Urothelial Cancer
por: Lindner, Andrea Katharina, et al.
Publicado: (2022)

Lynch Syndrome: Its Impact on Urothelial Carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2021)

Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Long term disease free survival with multimodal therapy in small cell bladder cancer
por: Heidegger, Isabel, et al.
Publicado: (2016)

The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study
por: Pichler, Renate, et al.
Publicado: (2017)

Organ-Sparing Surgery in Testicular Tumor: Is This the Right Approach for Lesions ≤ 20 mm?
por: Staudacher, Nina, et al.
Publicado: (2020)

A presumed extragonadal germ cell tumor that turned out to be a gastric cancer—a case report
por: Kafka, Mona, et al.
Publicado: (2021)

Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
por: Pichler, Renate, et al.
Publicado: (2016)

CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2023)

Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer—a valid option for cisplatin-unfit patients?
por: Arnold, C. R., et al.
Publicado: (2021)

Do we need repeated CT imaging in uncomplicated blunt renal injuries? Experiences of a high-volume urological trauma centre
por: Lindner, Andrea Katharina, et al.
Publicado: (2022)

Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2
por: Pichler, Renate, et al.
Publicado: (2023)

Adenomatoid tumor of the testis mimicking malignant testicular cancer on multiparametric ultrasound
por: Pichler, Renate, et al.
Publicado: (2018)

Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors: A National Cancer Registry Study in Austria
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
por: Pichler, Renate, et al.
Publicado: (2019)

A chemokine network of T cell exhaustion and metabolic reprogramming in renal cell carcinoma
por: Pichler, Renate, et al.
Publicado: (2023)

BCG Induced Necrosis of the Entire Bladder Urothelium
por: Krönig, Malte, et al.
Publicado: (2015)

Differences in Shedding of the Interleukin-11 Receptor by the Proteases ADAM9, ADAM10, ADAM17, Meprin α, Meprin β and MT1-MMP
por: Sammel, Martin, et al.
Publicado: (2019)

BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)

Organ-sparing surgery of penile cancer: higher rate of local recurrence yet no impact on overall survival
por: Lindner, Andrea Katharina, et al.
Publicado: (2019)

Regulation of Fibrotic Processes in the Liver by ADAM Proteases
por: Schmidt-Arras, Dirk, et al.
Publicado: (2019)

High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
por: Pichler, Renate, et al.
Publicado: (2018)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer
por: Pichler, Renate, et al.
Publicado: (2016)

Blockade of the protease ADAM17 ameliorates experimental pancreatitis
por: Saad, Mohamed I., et al.
Publicado: (2022)

Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)

BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis
por: Schwarzer, Katja, et al.
Publicado: (2010)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
por: Lim, Chun Jye, et al.
Publicado: (2021)

The cysteine-rich domain regulates ADAM protease function in vivo
por: Smith, Katherine M., et al.
Publicado: (2002)

The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
por: Duffy, Michael J, et al.
Publicado: (2011)

ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study
por: Zielinski, Valerie, et al.
Publicado: (2012)

Recognition and Treatment of BCG Failure in Bladder Cancer
por: Lightfoot, Andrew J., et al.
Publicado: (2011)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

ADAM proteases involved in inflammation are differentially altered in patients with gastritis or ulcer
por: Erin, Nuray, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_scmvfpr1lbnjoadd5eev4lbnge